These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1313234)

  • 1. Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate.
    Treskes M; Nijtmans LG; Fichtinger-Schepman AM; van der Vijgh WJ
    Biochem Pharmacol; 1992 Mar; 43(5):1013-9. PubMed ID: 1313234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278.
    Treskes M; Holwerda U; Nijtmans LG; Pinedo HM; van der Vijgh WJ
    Cancer Chemother Pharmacol; 1992; 29(6):467-70. PubMed ID: 1314713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin.
    Treskes M; Holwerda U; Klein I; Pinedo HM; van der Vijgh WJ
    Biochem Pharmacol; 1991 Nov; 42(11):2125-30. PubMed ID: 1659819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytostatic activity of cisplatin in the presence of WR2721 and its thiol metabolite WR1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts.
    Treskes M; Nijtmans L; Fichtinger-Schepman AM; van der Vijgh WJ
    Anticancer Res; 1992; 12(6B):2261-5. PubMed ID: 1338281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.
    Treskes M; van der Vijgh WJ
    Cancer Chemother Pharmacol; 1993; 33(2):93-106. PubMed ID: 8261581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA.
    Los G; van Vugt MJ; den Engelse L; Pinedo HM
    Biochem Pharmacol; 1993 Oct; 46(7):1229-37. PubMed ID: 8216374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.
    Treskes M; Boven E; Holwerda U; Pinedo HM; van der Vijgh WJ
    Cancer Res; 1992 Apr; 52(8):2257-60. PubMed ID: 1313740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs.
    Sadowitz PD; Hubbard BA; Dabrowiak JC; Goodisman J; Tacka KA; Aktas MK; Cunningham MJ; Dubowy RL; Souid AK
    Drug Metab Dispos; 2002 Feb; 30(2):183-90. PubMed ID: 11792689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro protection from cisplatin-induced neurotoxicity by amifostine and its metabolite WR1065.
    Verstappen CC; Geldof AA; Postma TJ; Heimans JJ
    J Neurooncol; 1999 Aug; 44(1):1-5. PubMed ID: 10582662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reaction kinetics of cisplatin and its monoaquated species with the (potential) renal protecting agents (di)mesna and thiosulfate. Estimation of the effect of protecting agents on the plasma and peritoneal AUCs of CDDP.
    Leeuwenkamp OR; van der Vijgh WJ; Neijt JP; Pinedo HM
    Cancer Chemother Pharmacol; 1990; 27(2):111-4. PubMed ID: 2174306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iododeoxyuridine chemosensitization of cis-diamminedichloroplatinum(II) in human bladder cancer cells.
    Chi KH; Kunugi KA; Kinsella TJ
    Cancer Res; 1994 May; 54(10):2701-6. PubMed ID: 8168100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells.
    Blommaert FA; van Dijk-Knijnenburg HC; Dijt FJ; den Engelse L; Baan RA; Berends F; Fichtinger-Schepman AM
    Biochemistry; 1995 Jul; 34(26):8474-80. PubMed ID: 7599137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of sensitive and resistant IgM immunocytomas to cis-diamminedichloroplatinum (II) does not correlate with the platination level or with the formation or removal of DNA adducts.
    Vendrik CP; Fichtinger-Schepman AM; van Dijk-Knijnenburg WC; de Jong WH; van der Minnen AC; de Groot G; Berends GF; Steerenberg PA
    Cancer Chemother Pharmacol; 1997; 39(6):479-85. PubMed ID: 9118458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of the response to cisplatin of human ovarian cancer cell lines, originating from one tumor but with different sensitivity, with the recovery of DNA adducts.
    De Pooter CM; Van Oosterom AT; Scalliet PG; Maes RA; de Bruijn EA
    Biochem Pharmacol; 1996 Mar; 51(5):629-34. PubMed ID: 8615899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin- and carboplatin-DNA adducts: is PT-AG the cytotoxic lesion?
    Fichtinger-Schepman AM; van Dijk-Knijnenburg HC; van der Velde-Visser SD; Berends F; Baan RA
    Carcinogenesis; 1995 Oct; 16(10):2447-53. PubMed ID: 7586150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate.
    Gandara DR; Wiebe VJ; Perez EA; Makuch RW; DeGregorio MW
    Crit Rev Oncol Hematol; 1990; 10(4):353-65. PubMed ID: 2177606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between phosphorylated histone H2AX formation and cell survival in human microvascular endothelial cells (HMEC) as a function of ionizing radiation exposure in the presence or absence of thiol-containing drugs.
    Kataoka Y; Murley JS; Baker KL; Grdina DJ
    Radiat Res; 2007 Jul; 168(1):106-14. PubMed ID: 17723002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of diethyldithiocarbamate on cis-diamminedichloroplatinum(II)-induced cytotoxicity, DNA cross-linking, and gamma-glutamyl transpeptidase inhibition.
    Bodenner DL; Dedon PC; Keng PC; Borch RF
    Cancer Res; 1986 Jun; 46(6):2745-50. PubMed ID: 2870800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway.
    North S; El-Ghissassi F; Pluquet O; Verhaegh G; Hainaut P
    Oncogene; 2000 Feb; 19(9):1206-14. PubMed ID: 10713709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of amifostine on cisplatin induced DNA adduct formation and toxicity in malignant glioma and normal tissues in rat.
    Bergström P; Johnsson A; Bergenheim T; Henriksson R
    J Neurooncol; 1999 Mar; 42(1):13-21. PubMed ID: 10360475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.